# The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial

> **NCT02401828** · PHASE4 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 134 (actual)

## Conditions studied

- Human Immunodeficiency Virus

## Interventions

- **DRUG:** Dolutegravir

## Key facts

- **NCT ID:** NCT02401828
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 134 (ACTUAL)
- **Last updated:** 2020-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02401828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02401828, "The Dolutegravir Antiretroviral Mono-Therapy for HIV Trial". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT02401828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*